Market Cap 224.70M
Revenue (ttm) 0.00
Net Income (ttm) -294.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 446,100
Avg Vol 939,466
Day's Range N/A - N/A
Shares Out 54.41M
Stochastic %K 86%
Beta -1.50
Analysts Strong Sell
Price Target $20.43

Company Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to ad...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 231 6625
Address:
280 East Grand Avenue, South San Francisco, United States
Ommo
Ommo Aug. 4 at 2:57 AM
$ALMS 6250 share so far
0 · Reply
IN0V8
IN0V8 Aug. 3 at 2:23 AM
$ALMS Buying Opportunity / Price Target: $19.80 (+379.42%) 5 analysts that cover Alumis stock have a consensus rating of "Strong Buy" and an average price target of $19.8, which forecasts a 379.42% increase in the stock price over the next year. The lowest target is $14 and the highest is $25.
0 · Reply
SalmanAziz
SalmanAziz Aug. 1 at 1:57 PM
$ALMS picked some up here. The pipeline looks robust. Plus it has cash runway well into 2027. Setting a price target in double digit land by the end of 2025.
0 · Reply
SalmanAziz
SalmanAziz Aug. 1 at 10:46 AM
$ALMS when do ppl expect P3 results to be out?
0 · Reply
Fib7867
Fib7867 Jul. 26 at 8:15 PM
#myALMSanalysis $ALMS
0 · Reply
IN0V8
IN0V8 Jul. 25 at 2:30 PM
$ALMS Buy Wells Fargo initiates coverage with overweight rating and PT $17
0 · Reply
gulf29
gulf29 Jul. 25 at 12:28 PM
$ALMS and Holo strong liquidity. But Holo is not trusted
0 · Reply
JarvisFlow
JarvisFlow Jul. 25 at 11:30 AM
HC Wainwright & Co. has updated their rating for Alumis ( $ALMS ) to Buy with a price target of 14.
0 · Reply
DCRMIA
DCRMIA Jul. 25 at 10:43 AM
$ALMS "H.C. Wainwright maintains Alumis at ’buy’ with a price target of $14.00" https://www.investing.com/news/pro/hc-wainwright-maintains-alumis-at-buy-with-a-price-target-of-1400-4152939
0 · Reply
Heavytank2
Heavytank2 Jul. 25 at 10:42 AM
$ALMS I bought one share. Here comes the drop. 😂 For real. I'll get in soon but since that's the usual MO I'll wait a day or two.
0 · Reply
Latest News on ALMS
Alumis Completes Merger with ACELYRIN

May 21, 2025, 9:10 AM EDT - 2 months ago

Alumis Completes Merger with ACELYRIN


Alumis Stockholders Approve Merger with ACELYRIN

May 13, 2025, 1:00 PM EDT - 2 months ago

Alumis Stockholders Approve Merger with ACELYRIN


Alumis and ACELYRIN Announce Amended Merger Agreement

Apr 21, 2025, 6:30 AM EDT - 3 months ago

Alumis and ACELYRIN Announce Amended Merger Agreement


Top 3 Health Care Stocks That May Crash In Q2

Apr 7, 2025, 11:23 AM EDT - 4 months ago

Top 3 Health Care Stocks That May Crash In Q2

CMRX DERM


Alumis to Present at Leerink's 2025 Global Healthcare Conference

Mar 10, 2025, 8:00 AM EDT - 5 months ago

Alumis to Present at Leerink's 2025 Global Healthcare Conference


Alumis Strengthens Leadership Team with Key Appointments

Jan 28, 2025, 8:00 AM EST - 6 months ago

Alumis Strengthens Leadership Team with Key Appointments


Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Oct 4, 2024, 2:00 AM EDT - 10 months ago

Alumis: Could This Broken Immunology IPO Become The Next Amgen?


Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Sep 16, 2024, 4:32 PM EDT - 11 months ago

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases


Alumis to Participate in Upcoming September Investor Conferences

Sep 3, 2024, 4:29 PM EDT - 11 months ago

Alumis to Participate in Upcoming September Investor Conferences


Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Jun 28, 2024, 12:58 PM EDT - 1 year ago

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut


Alumis Announces Pricing of Initial Public Offering

Jun 27, 2024, 11:57 PM EDT - 1 year ago

Alumis Announces Pricing of Initial Public Offering


Alumis eyes $300 million in proceeds in IPO

Jun 24, 2024, 7:18 AM EDT - 1 year ago

Alumis eyes $300 million in proceeds in IPO


Alumis' $100 Million IPO: Promising Psoriasis Treatment Results

Jun 11, 2024, 12:25 PM EDT - 1 year ago

Alumis' $100 Million IPO: Promising Psoriasis Treatment Results


Ommo
Ommo Aug. 4 at 2:57 AM
$ALMS 6250 share so far
0 · Reply
IN0V8
IN0V8 Aug. 3 at 2:23 AM
$ALMS Buying Opportunity / Price Target: $19.80 (+379.42%) 5 analysts that cover Alumis stock have a consensus rating of "Strong Buy" and an average price target of $19.8, which forecasts a 379.42% increase in the stock price over the next year. The lowest target is $14 and the highest is $25.
0 · Reply
SalmanAziz
SalmanAziz Aug. 1 at 1:57 PM
$ALMS picked some up here. The pipeline looks robust. Plus it has cash runway well into 2027. Setting a price target in double digit land by the end of 2025.
0 · Reply
SalmanAziz
SalmanAziz Aug. 1 at 10:46 AM
$ALMS when do ppl expect P3 results to be out?
0 · Reply
Fib7867
Fib7867 Jul. 26 at 8:15 PM
#myALMSanalysis $ALMS
0 · Reply
IN0V8
IN0V8 Jul. 25 at 2:30 PM
$ALMS Buy Wells Fargo initiates coverage with overweight rating and PT $17
0 · Reply
gulf29
gulf29 Jul. 25 at 12:28 PM
$ALMS and Holo strong liquidity. But Holo is not trusted
0 · Reply
JarvisFlow
JarvisFlow Jul. 25 at 11:30 AM
HC Wainwright & Co. has updated their rating for Alumis ( $ALMS ) to Buy with a price target of 14.
0 · Reply
DCRMIA
DCRMIA Jul. 25 at 10:43 AM
$ALMS "H.C. Wainwright maintains Alumis at ’buy’ with a price target of $14.00" https://www.investing.com/news/pro/hc-wainwright-maintains-alumis-at-buy-with-a-price-target-of-1400-4152939
0 · Reply
Heavytank2
Heavytank2 Jul. 25 at 10:42 AM
$ALMS I bought one share. Here comes the drop. 😂 For real. I'll get in soon but since that's the usual MO I'll wait a day or two.
0 · Reply
DCRMIA
DCRMIA Jul. 25 at 9:38 AM
$ALMS "Wells Fargo initiates coverage of Alumis at ’overweight’ with a price target of $17.00" https://www.investing.com/news/pro/wells-fargo-initiates-coverage-of-alumis-at-overweight-with-a-price-target-of-1700-4152724
0 · Reply
777Dog
777Dog Jul. 24 at 1:51 PM
$ALMS $20 target legit...broke resistance...higher high after higher low... The trend is now our friend... Good luck everybody
0 · Reply
DCRMIA
DCRMIA Jul. 24 at 12:55 PM
$ALMS "Alumis completes enrollment in lupus treatment phase 2b trial" https://www.investing.com/news/company-news/alumis-completes-enrollment-in-lupus-treatment-phase-2b-trial-93CH-4150550
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 24 at 2:14 AM
$ALMS PT 4.25
0 · Reply
JazzyJ03
JazzyJ03 Jul. 23 at 7:39 PM
$ALMS Looks like it bottomed out and least on monthly.
0 · Reply
777Dog
777Dog Jul. 22 at 2:33 AM
$ALMS Covid causes auto-immunity including the thyroid...who knew...AI knew... "COVID-19 infection can trigger or worsen psoriasis flares. This may be due to the inflammatory response caused by the virus." "Evidence also links TYK2-dependent pathways to the overall immune dysregulation seen in autoimmune diseases, including those affecting the thyroid." Tyk2 inhibitors...$$$$...$20 target is legit... https://slaynews.com/news/stanford-scientists-link-spike-thyroid-eye-disease-covid-vaccines/
0 · Reply
777Dog
777Dog Jul. 22 at 2:16 AM
$ALMS Algo stopped the AM dump, but still wants to drop it...the problem for our Algo it that the one year target is legit $20 and phase III is a shoo-in... the Algo masters know retail is impatient...tutes are not impatient...those puts may stay out of the money if a big tute(s) starts accumulating 6 months in advance or they are betting on a sale of the company to a Sanofi... multi billion dollar autoimmunity markets, and we currently have an oral that is best in class for many/most very common autoimmune diseases...and a second molecule that is first in class for neuroimmunity...very real possibility of nontoxic oral therapy for MS, Parkinson's, and Alsheimer's...f'ing home run...sitting pretty with months to go...who knows...maybe Algo takes it down, maybe not...
1 · Reply
777Dog
777Dog Jul. 21 at 12:29 PM
$ALMS just found this reddit thread...prettymuch covers the bases... https://www.reddit.com/r/CountryDumb/comments/1lj7wt4/comment/n0e8pyx/?context=3&share_id=uMcpUCXqwls9Zmmk4asFZ&utm_content=1&utm_medium=ios_app&utm_name=ioscss&utm_source=share&utm_term=1
0 · Reply
BluntForceOptions
BluntForceOptions Jul. 19 at 7:51 PM
$ALMS Anyone looking at the unusually large put position in Alumis, specifically the 30,000+ open Oct ’25 $2.50 puts, here’s how I’m interpreting it: Yes, it’s a big number (~3M shares notional), and yes, the options chain is generally illiquid. But rather than a directional bearish bet or a hedge on dilution (which seems unlikely given the ~$700M in cash, this setup, IMO, looks more like a range-bound premium strategy. Consider this: • There was notable call OI in the July $5 and $7.50 strikes -- now expired -- which likely reflects short call selling into strength • On the flip side, those Oct $2.50 puts may be cash-secured puts -- positioning to accumulate lower if it pulls back, while collecting premium • This reflects a neutral to modestly bullish stance, expecting the stock to stay contained between that $2.50–$5.00 zone for now • No major open long calls or long puts elsewhere in the chain -- which supports a view that this is more about volatility suppression and yield harvesting, not directional conviction Could be an institutional player playing both sides: collecting premium from short-dated calls above the range and selling downside puts below it -- happy to own it lower, not chasing upside, and not expecting a collapse either. Just my read, FWIW
0 · Reply
Rider_on_the_Stonk
Rider_on_the_Stonk Jul. 18 at 6:30 PM
$ALMS why couldn't SLRN just stay independent??????? ALMS is the worst
0 · Reply
LexDiamonds
LexDiamonds Jul. 16 at 9:11 AM
0 · Reply
777Dog
777Dog Jul. 15 at 5:29 PM
$ALMS Check out the SEC documents...Sanam is making bank taking her job... Why would a company pay a crapload to retain a lawyer with M&A expertise...Hmmm, that sure is curious... Drop it, cause I want more...
0 · Reply